CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

Neurology. 2002 Aug 27;59(4):627-9. doi: 10.1212/wnl.59.4.627.

Abstract

In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau(231)) in CSF correlate with progression of cognitive decline. High CSF p-tau(231) levels at baseline, but not total tau protein levels, correlated with cognitive decline and conversion from MCI to AD. Independently, old age and APOE-epsilon 4 carrier status were predictive as well. Our data indicate that an increased p-tau(231) level is a potential risk factor for cognitive decline in patients with MCI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / complications
  • Alzheimer Disease / diagnosis
  • Apolipoprotein E4
  • Apolipoproteins E / genetics
  • Biomarkers / cerebrospinal fluid
  • Cognition Disorders / cerebrospinal fluid*
  • Cognition Disorders / complications
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / genetics
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Phosphorylation
  • Predictive Value of Tests
  • Regression Analysis
  • Risk Factors
  • Threonine / metabolism
  • tau Proteins / cerebrospinal fluid*
  • tau Proteins / metabolism*

Substances

  • Apolipoprotein E4
  • Apolipoproteins E
  • Biomarkers
  • tau Proteins
  • Threonine